



# Targets of Antibody-Drug Conjugates in NSCLC

## Diagnostics, Emerging Therapies, and Future Prospects

**MONDAY, 12 SEPTEMBER, 2022 | 18:30 – 20:00 CEST**

7.3.H - HONFLEUR AUDITORIUM, HALL 7, LEVEL 7.3,  
PARIS EXPO PORTE DE VERSAILLES, PARIS, FRANCE

A Medscape **LIVE!** EVENT

### MODERATOR



**Enriqueta Felip, MD, PhD**  
Medical Oncologist  
Head, Thoracic Malignancies  
Vall d'Hebron University Hospital  
Barcelona, Spain

### PANELISTS



**Egbert Smit, MD**  
Professor of Pulmonology  
Leiden University Medical Center  
Leiden, the Netherlands



**Michael Thomas, MD**  
Professor of Medicine  
Head, Thoracic Oncology  
Thoraxklinik-Heidelberg  
Heidelberg University  
Heidelberg, Germany

### AGENDA

**18:30**

***Personalizing Treatment in NSCLC: Recent Developments***

Enriqueta Felip, MD, PhD

**18:35**

***Novel ADC Targets in NSCLC: Rationale and Diagnostic Considerations***

Michael Thomas, MD

**18:55**

***Which Patients May Benefit From Emerging ADCs in NSCLC: Explaining the Clinical Trial Data***

Egbert Smit, MD

**19:20**

***Preparing the Clinics and Future Prospects***

Enriqueta Felip, MD, PhD

**19:40**

**Q&A Session**

All Faculty

**19:58**

**Concluding Remarks**

Enriqueta Felip, MD, PhD